KYM Holdings Berhad (8362)
XKLS 
NASDAQ (NMS) Primary XKLS Summary
8362 Chart
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million in FY25, reflecting aggressive advancement of KT-621 and KT-579 into mid-stage trials, prioritizing long-term value over near-term profitability. KT-621's Phase 2b trials in atopic dermatitis and eosinophilic asthma are key 2027 catalysts; KT-579's Phase 1 data in autoimmune diseases is expected in 2H26.
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
KYM Holdings Berhad (8362) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has KYM Holdings Berhad ever had a stock split?
KYM Holdings Berhad Profile
| Biotechnology Industry | Healthcare Sector | Nello Mainolfi CEO | XKLS Exchange | MYL8362OO005 ISIN |
| US Country | 208 Employees | - Last Dividend | - Last Split | 21 Aug 2020 IPO Date |
Overview
Kymera Therapeutics, Inc. is a pioneering biopharmaceutical company committed to the discovery and development of innovative small molecule therapeutics that leverage the body’s natural protein degradation system to specifically target and eliminate disease-causing proteins. Established in 2015 and based in Watertown, Massachusetts, Kymera Therapeutics is at the forefront of harnessing proteolysis targeting chimeras (PROTACs) technology to address some of the most challenging diseases in immunology, oncology, and other fields.
Products and Services
- IRAK4 Program
This program is a testament to the company’s innovative approach, currently in Phase II clinical trial targeting a range of immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis. By focusing on the selective degradation of the IRAK4 protein, Kymera aims to offer novel treatments for conditions with significant unmet needs.
- STAT3 Program
Geared towards the treatment of hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis, the STAT3 program represents Kymera Therapeutics' venture into oncology and autoimmune disorders. Leveraging the degradation of STAT3, this program seeks to provide effective therapies for diseases that are currently hard to treat.
- MDM2 Program
Another highlight in Kymera’s pipeline is the MDM2 program, dedicated to addressing both hematological malignancies and solid tumors. By exploiting the degradation pathway of the MDM2 protein, this program explores new horizons in cancer treatment, showcasing the flexibility and potential of PROTACs technology.
- STAT6
The STAT6 project focuses on tackling Type 2 inflammation present in allergic diseases. Through the selective degradation of the STAT6 protein, Kymera Therapeutics is venturing into the realm of allergy and immunology, aiming to develop therapies that can significantly improve patient outcomes in allergic conditions.
- TYK2
Addressing inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus, the TYK2 program underscores Kymera Therapeutics' commitment to inflammatory diseases. By targeting the TYK2 protein for degradation, the company is working on crafting innovative solutions that could transform the treatment landscape for patients suffering from these chronic conditions.
